1
|
Jackson MJ, Vaughan G, Ledley FD. Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010-2019: a cross-sectional analysis. BMJ Open 2024; 14:e076542. [PMID: 38471684 PMCID: PMC10936494 DOI: 10.1136/bmjopen-2023-076542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Accepted: 02/20/2024] [Indexed: 03/14/2024] Open
Abstract
OBJECTIVES Pharmaceutical innovation can contribute to reducing the burden of disease in human populations. This research asks whether products approved by the US Food and Drug Administration (FDA) from 2010 to 2019 and expedited review programmes incentivising development of products for serious disease were aligned with the US or global burden of disease. DESIGN Cross-sectional study. OUTCOME MEASURES Association of FDA product approvals (2010-2019), first approved indications, designations for expedited review with the burden of disease (disability-adjusted life years (DALYs)), years of life lost (YLL) and years of life lived with disability (YLD) for 122 WHO Global Health Estimates (GHE) conditions in US and global (ex-US) populations. RESULTS The FDA approved 387 drugs in 2010-2019 with lead indications associated with 59/122 GHE conditions. Conditions with at least one new drug had greater US DALYs (p=0.001), US YLL (p<0.001), global DALYs (p=0.030) and global YLL (p=0.004) but not US YLD (p=0.158) or global YLD (p=0.676). Most approvals were for conditions in the top quartile of US DALYs or YLL, but <27% were for conditions in the top quartile of global DALYs or YLL. The likelihood of a drug having one or more designations for expedited review programmes was negatively associated (OR<1) with US DALYs, US YLD and global YLD. There was a weak negative association with global DALYs and a weak positive association (OR>1) with US and global YLL. CONCLUSIONS FDA drug approvals from 2010 to 2019 were more strongly aligned with US than global disease burden. Designations for expedited review were not aligned with either the US or global burdens of disease and may inadvertently disincentivise development of products addressing global disease burdens. These results may inform policies to better align pharmaceutical innovation with the burdens of disease.
Collapse
Affiliation(s)
- Matthew J Jackson
- Bentley University, Waltham, Massachusetts, USA
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, USA
| | | | - Fred D Ledley
- Bentley University, Waltham, Massachusetts, USA
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, USA
| |
Collapse
|
2
|
Ledley FD, Cleary EG. NIH funding for patents that contribute to market exclusivity of drugs approved 2010-2019 and the public interest protections of Bayh-Dole. PLoS One 2023; 18:e0288447. [PMID: 37494368 PMCID: PMC10370755 DOI: 10.1371/journal.pone.0288447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 06/27/2023] [Indexed: 07/28/2023] Open
Abstract
Previous studies have shown that National Institutes of Health (NIH) funding contributed >$187 billion for basic or applied research related to the 356 drugs approved 2010-2019. This analysis asks how much of this funding led to patents cited as providing market exclusivity, patents that would be subject to the provisions of the Bayh-Dole Act that promote and protect the public interest. The method involves identifying published research in PubMed related to the approved drugs (applied research) or their targets (basic research). NIH-funded projects (grants) funding these publications and patents arising from these projects were both identified in RePORT. Patents cited as providing market exclusivity were identified in DrugPatentWatch (which incorporates FDA Orange Book). NIH funded basic or applied research related to all 313 FDA-approved drugs 2010-2019 with at least one patent in DrugPatentWatch. This research comprised 350 thousand publications (9% applied research; 91% basic research) supported by 341 thousand fiscal years (project years) of NIH funding and $164 billion in NIH project year costs (17% applied research; 83% basic research). These NIH projects also produced 22,360 patents, 119 of which were cited in DrugPatentWatch as protecting 34/313 drugs. These patents were associated with 769 project years of NIH funding (0.23% total) and project year costs of $0.95 billion (0.59% total). Overall, only 1.5% of total NIH funding for applied research and 0.38% of total NIH funding for basic research was associated with patents in DrugPatentWatch. This analysis shows that very little of the NIH funding for research that contributes to new drug approvals leads to patents that provide market exclusivity and are subject to the provisions of the Bayh-Dole Act that promote the public interest in practical applications of the research, reasonable use and pricing, and a return on this public sector investment. This suggests that the Bayh-Dole Act is limited in its ability to protect the public interest in the pharmaceutical innovations driven by NIH-funded research.
Collapse
Affiliation(s)
- Fred D Ledley
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America
- Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts, United States of America
- Department of Management, Bentley University, Waltham, Massachusetts, United States of America
| | - Ekaterina Galkina Cleary
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America
- Department of Mathematical Sciences, Bentley University, Waltham, Massachusetts, United States of America
| |
Collapse
|
3
|
Zhou EW, Jackson MJ, Ledley FD. Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry. JAMA Health Forum 2023; 4:e231921. [PMID: 37450296 PMCID: PMC10349341 DOI: 10.1001/jamahealthforum.2023.1921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Accepted: 04/07/2023] [Indexed: 07/18/2023] Open
Abstract
Importance The launch of the Advanced Research Projects Agency for Health to advance new cures and address public concern regarding drug prices has raised questions about the roles of government and industry in drug development. Objectives To compare National Institutes of Health (NIH) spending on phased clinical development of approved drugs with that by industry. Design This cross-sectional study examined NIH funding for published research reporting the results of phased clinical trials of drugs approved between 2010 and 2019 and compared the findings with reported industry spending estimates. Data analysis was performed between May 2021 and August 2022 using PubMed data from January 1999 through October 2021 and NIH Research Portfolio Online Reporting Tools Expenditures and Results data from January 1999 through December 2020. Exposures Drugs approved between 2010 and 2019. Main Outcome and Measures National Institutes of Health funding for published research describing applied research on approved drugs, basic research on their biological targets, and phased clinical trials related to drugs approved between 2010 and 2019 were evaluated using Mann-Whitney U tests. All costs were inflation adjusted to 2018. Results National Institutes of Health funding for basic or applied research related to 386 of 387 drugs approved between 2010 and 2019 totaled $247.3 billion. Of this amount, $8.1 billion (3.3%) was related to phased clinical development. This funding contributed to 12 340 publications on phased clinical trial results involving 240 of 387 (62.0%) drugs. Average NIH spending was $33.8 million per drug, including $13.9 million per drug for phase 1, $22.2 million per drug for phase 2, and $12.9 million per drug for phase 3 trials. Spending by NIH on phased development represented 9.8% to 10.7% of estimated industry spending, including 24.6% to 25.3% of estimated phase 1, 21.4% to 23.2% of phase 2, and 3.7% to 4.3% of phase 3 costs. Considering 60 products for which estimated industry costs were publicly available, NIH spending on clinical trials was significantly lower than estimated industry spending (sum of averages, $54.9 million per drug; mean difference, $326.0 million; 95% CI, $235.6-$416.4 million; 2-tailed paired t test P < .001). More than 90% of NIH funding came through cooperative agreements or program projects and centers, while 3.3% of NIH funding came through investigator-initiated research projects. Conclusions and Relevance In this cross-sectional study, NIH funding for phased clinical development of drugs approved between 2010 and 2019 represented a small fraction of NIH spending on pharmaceutical innovation. This spending focused primarily on early-phase clinical trials and research capacity and was significantly less than estimated industry spending on clinical development. These results may inform the efficient allocation of government funding to advance pharmaceutical innovation.
Collapse
Affiliation(s)
- Edward W. Zhou
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts
- Department of Natural and Applied Sciences, Bentley University, Waltham, Massachusetts
| | - Matthew J. Jackson
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts
| | - Fred D. Ledley
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts
- Department of Natural and Applied Sciences, Bentley University, Waltham, Massachusetts
- Department of Management, Bentley University, Waltham, Massachusetts
| |
Collapse
|
4
|
Galkina Cleary E, Jackson MJ, Zhou EW, Ledley FD. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019. JAMA Health Forum 2023; 4:e230511. [PMID: 37115539 PMCID: PMC10148199 DOI: 10.1001/jamahealthforum.2023.0511] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023] Open
Abstract
Importance Government and the pharmaceutical industry make substantive contributions to pharmaceutical innovation. This study compared the investments by the National Institutes of Health (NIH) and industry and estimated the cost basis for assessing the balance of social and private returns. Objectives To compare NIH and industry investments in recent drug approvals. Design, Setting, and Participants This cross-sectional study of NIH funding associated with drugs approved by the FDA from 2010 to 2019 was conducted from May 2020 to July 2022 and accounted for basic and applied research, failed clinical candidates, and discount rates for government spending compared with analogous estimates of industry investment. Main Outcomes and Measures Costs from the NIH for research associated with drug approvals. Results Funding from the NIH was contributed to 354 of 356 drugs (99.4%) approved from 2010 to 2019 totaling $187 billion, with a mean (SD) $1344.6 ($1433.1) million per target for basic research on drug targets and $51.8 ($96.8) million per drug for applied research on products. Including costs for failed clinical candidates, mean (SD) NIH costs were $1441.5 ($1372.0) million per approval or $1730.3 ($1657.6) million per approval, estimated with a 3% discount rate. The mean (SD) NIH spending was $2956.0 ($3106.3) million per approval with a 10.5% cost of capital, which estimates the cost savings to industry from NIH spending. Spending and approval by NIH for 81 first-to-target drugs was greater than reported industry spending on 63 drugs approved from 2010 to 2019 (difference, -$1998.4 million; 95% CI, -$3302.1 million to -$694.6 million; P = .003). Spending from the NIH was not less than industry spending considering clinical failures, a 3% discount rate for NIH spending, and a 10.5% cost of capital for the industry (difference, -$1435.3 million; 95% CI, -$3114.6 million to $244.0 million; P = .09) or when industry spending included prehuman research (difference, -$1394.8 million; 95% CI, -$3774.8 million to $985.2 million; P = .25). Accounting for spillovers of NIH-funded basic research on drug targets to multiple products, NIH costs were $711.3 million with a 3% discount rate, which was less than the range of reported industry costs with 10.5% cost of capital. Conclusions and Relevance The results of this cross-sectional study found that NIH investment in drugs approved from 2010 to 2019 was not less than investment by the pharmaceutical industry, with comparable accounting for basic and applied research, failed clinical trials, and cost of capital or discount rates. The relative scale of NIH and industry investment may provide a cost basis for calibrating the balance of social and private returns from investments in pharmaceutical innovation.
Collapse
Affiliation(s)
- Ekaterina Galkina Cleary
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts
- Exponent, Inc
- Department of Mathematical Sciences, Bentley University, Waltham, Massachusetts
| | - Matthew J Jackson
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts
- Department of Natural and Applied Sciences, Bentley University, Waltham, Massachusetts
| | - Edward W Zhou
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts
- Department of Natural and Applied Sciences, Bentley University, Waltham, Massachusetts
| | - Fred D Ledley
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts
- Department of Natural and Applied Sciences, Bentley University, Waltham, Massachusetts
- Department of Management, Bentley University, Waltham, Massachusetts
| |
Collapse
|
5
|
Shah P, Vaughan G, Ledley FD. Comparing the economic terms of biotechnology licenses from academic institutions with those between commercial firms. PLoS One 2023; 18:e0283887. [PMID: 37000836 PMCID: PMC10065281 DOI: 10.1371/journal.pone.0283887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Accepted: 02/27/2023] [Indexed: 04/01/2023] Open
Abstract
Licenses of drug-related biotechnologies from academic institutions to commercial firms are intended to promote practical applications of public sector research and a return on government investments in biomedical science. This empirical study compares the economic terms of 239 biotechnology licenses from academic institutions to biotechnology companies with 916 comparable licenses between commercial firms. Academic licenses had lower effective royalty rates (median 3% versus 8%, p<0.001), deal size (median $0.9M versus $31.0M, p<0.001), and precommercial payments (median $1.1M versus $25.4M, p<0.001) than corporate licenses. Controlling for the clinical phase of the most advanced product included in the license reduced the median difference in effective royalty rate between academic and corporate licenses from 5% (95% CI 4.3-5.7) to 3% (95% C.I. 2.4-3.6) but did not change the difference in deal size or precommercial payments. Excluding licenses for co-commercialization did not change the effective royalty rate but reduced the median difference in deal size from $15.8M (95% CI 14.9-16.6) to $11.4M (95% CI 10.4-12.3) and precommercial payments from $9.0M (95% CI 8.0-10.0) to $7.6M (95% CI 6.8-8.4). Controlling for deal terms including exclusivity, equity, or R&D in multivariable regression had no substantive effect on the difference in economic terms. This analysis suggests the economic returns associated with biotechnology licenses from academic institutions are systematically lower than licenses between commercial firms and that this difference is only partially accounted for by differences in the intrinsic terms of the license agreements. These results are discussed in the context of a reasonable royalty rate, recognizing that factors extrinsic to the license agreement may reasonably impact the negotiated value of the license, as well as economic theories that view government as an early investor in innovation and technology licenses as a mechanism for achieving a return on investment.
Collapse
Affiliation(s)
- Prateet Shah
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America
| | - Gregory Vaughan
- Department of Mathematical Sciences, Bentley University, Waltham, Massachusetts, United States of America
| | - Fred D Ledley
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America
- Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts, United States of America
- Department of Management, Bentley University, Waltham, Massachusetts, United States of America
| |
Collapse
|
6
|
Kiszewski AE, Cleary EG, Jackson MJ, Ledley FD. NIH funding for vaccine readiness before the COVID-19 pandemic. Vaccine 2021; 39:2458-2466. [PMID: 33781600 PMCID: PMC7938738 DOI: 10.1016/j.vaccine.2021.03.022] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 02/26/2021] [Accepted: 03/04/2021] [Indexed: 12/12/2022]
Abstract
Rapid development of vaccines for COVID-19 has relied on the application of existing vaccine technologies. This work examines the maturity of ten technologies employed in candidate vaccines (as of July 2020) and NIH funding for published research on these technologies from 2000–2019. These technologies vary from established platforms, which have been used successfully in approved products, to emerging technologies with no prior clinical validation. A robust body of published research on vaccine technologies was supported by 16,358 fiscal years of NIH funding totaling $17.2 billion from 2000–2019. During this period, NIH funding for published vaccine research against specific pandemic threats such as coronavirus, Zika, Ebola, and dengue was not sustained. NIH funding contributed substantially to the advance of technologies available for rapid development of COVID-19 vaccines, suggesting the importance of sustained public sector funding for foundational technologies in the rapid response to emerging public health threats.
Collapse
Affiliation(s)
- Anthony E Kiszewski
- Department of Natural & Applied Sciences, Bentley University, Waltham, MA 02452, United States
| | - Ekaterina Galkina Cleary
- Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452, United States; Department of Mathematical Sciences, Bentley University, Waltham, MA 02452, United States
| | - Matthew J Jackson
- Department of Natural & Applied Sciences, Bentley University, Waltham, MA 02452, United States; Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452, United States
| | - Fred D Ledley
- Department of Natural & Applied Sciences, Bentley University, Waltham, MA 02452, United States; Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452, United States; Department of Management, Bentley University, Waltham, MA 02452, United States.
| |
Collapse
|
7
|
Cleary EG, McNamee LM, de Boer S, Holden J, Fitzgerald L, Ledley FD. Comparing long-term value creation after biotech and non-biotech IPOs, 1997-2016. PLoS One 2021; 16:e0243813. [PMID: 33406113 PMCID: PMC7787373 DOI: 10.1371/journal.pone.0243813] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Accepted: 11/28/2020] [Indexed: 11/21/2022] Open
Abstract
We compared the financial performance of 319 BIOTECH companies focused on developing therapeutics with IPOs from 1997-2016, to that of paired, non-biotech CONTROL companies with concurrent IPO dates. BIOTECH companies had a distinctly different financial structure with high R&D expense, little revenue, and negative profits (losses), but a similar duration of listing on public markets and frequency of acquisitions. Through 2016, BIOTECH and CONTROL companies had equivalent growth in market cap and shareholder value (>$100 billion), but BIOTECH companies had lower net value creation ($93 billion vs $411 billion). Both cohorts exhibited a high-risk/high reward pattern of return, with the majority losing value, but many achieving growth multiples. While investments in biotechnology are often considered to be distinctively risky, we conclude that value creation by biotech companies after IPO resembles that of non-biotech companies at a similar stage and does not present a disproportionate investment risk.
Collapse
Affiliation(s)
- Ekaterina Galkina Cleary
- Department of Mathematical Sciences, Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America
| | - Laura M. McNamee
- Department of Natural & Applied Science, Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America
| | - Skyler de Boer
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America
| | - Jeremy Holden
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America
| | - Liam Fitzgerald
- Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America
| | - Fred D. Ledley
- Department of Natural & Applied Science, Department of Management, Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America
| |
Collapse
|
8
|
McNamee LM, Cleary EG, Zhang S, Salim U, Ledley FD. Late-stage Product Development and Approvals by Biotechnology Companies After Initial Public Offering, 1997-2016. Clin Ther 2020; 43:156-171.e15. [PMID: 33380363 DOI: 10.1016/j.clinthera.2020.11.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2020] [Revised: 11/20/2020] [Accepted: 11/22/2020] [Indexed: 10/22/2022]
Abstract
PURPOSE This work describes the late-stage product portfolios of the biotechnology companies that completed initial public offerings (IPOs) from 1997 to 2016. We asked whether these emerging companies continue to develop innovative, biologic products and produce the innovation promised by the early biotechnology industry. METHODS We identified therapeutic products that reached Phase III development from 1997 to 2016, the characteristics of the products, the dates of the initiation of Phase III and product approval, proxy indicators of the innovativeness of each product, and the contribution of each biotechnology company. Companies were characterized by IPO window and clinical status of the most advanced product at IPO. Time from IPO to Phase III or approval, and the estimated probability of a company having a product advance to these milestones, were examined using Kaplan-Meier analysis. FINDINGS A total of 319 biotechnology companies completed IPOs from 1997 to 2016. These companies contributed to the development of 367 products that progressed to Phase III, and of 144 new drug approvals, through 2016. The estimated probability of a company having a product reach Phase III was 78%, and the estimated probability of a company receiving at least 1 product approval was 52%, with most approvals occurring >5 years after IPO. Small-molecule drugs represented 74% of products reaching Phase III and 78% of approvals. Reformulations represented 36% of Phase III products and 46% of approvals. The estimated probability of product approval was significantly higher for reformulations than new molecular entities (NMEs) and slightly higher for small molecules than biologics. The estimated probability of a company receiving product approval varied significantly by IPO window and was greater for companies with Phase III products at IPO (74%). These companies contributed to the development of 78 NMEs, 44% of which were classified as first in class, initiating development of 69% and contributing to the clinical development of 96%. These products represented 16% of all NMEs and 28% of biologics approved between 1997 and 2016. Seven products achieved per-annum sales of >$1 billion during the study period. IMPLICATIONS The majority of emerging publicly owned biotechnology companies contribute to products that advance to Phase III development and approval, although these companies are no longer distinctively focused on biologic products.
Collapse
Affiliation(s)
- Laura M McNamee
- Center for Integration of Science and Industry, Bentley University, Waltham, MA, USA; Department of Natural & Applied Science, Bentley University, Waltham, MA, USA
| | - Ekaterina Galkina Cleary
- Center for Integration of Science and Industry, Bentley University, Waltham, MA, USA; Department of Mathematical Science, Bentley University, Waltham, MA, USA
| | - Sunyi Zhang
- Center for Integration of Science and Industry, Bentley University, Waltham, MA, USA
| | - Usama Salim
- Center for Integration of Science and Industry, Bentley University, Waltham, MA, USA
| | - Fred D Ledley
- Center for Integration of Science and Industry, Bentley University, Waltham, MA, USA; Department of Natural & Applied Science, Bentley University, Waltham, MA, USA; Department of Management, Bentley University, Waltham, MA, USA.
| |
Collapse
|
9
|
Cleary EG, Ledley FD. NIH funding for research underlying new cancer therapies. Lancet Oncol 2020; 21:755-757. [PMID: 32502441 DOI: 10.1016/s1470-2045(20)30235-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Revised: 03/30/2020] [Accepted: 04/06/2020] [Indexed: 10/24/2022]
Affiliation(s)
- Ekaterina Galkina Cleary
- Department of Mathematical Sciences, Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452, USA
| | - Fred D Ledley
- Department of Natural and Applied Science, Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452, USA; Department of Management, Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452, USA.
| |
Collapse
|
10
|
Wernick NLB, Ledley FD. We Don't Have to Lose STEM Students to Business. J Microbiol Biol Educ 2020; 21:jmbe-21-43. [PMID: 32431771 PMCID: PMC7198222 DOI: 10.1128/jmbe.v21i1.2095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 02/18/2020] [Indexed: 06/11/2023]
Abstract
Most undergraduate students who leave STEM majors before graduation choose careers in business. This article argues that better integrating business opportunities and context into the STEM curriculum could advance STEM learning, motivate students to remain in STEM as majors, and cultivate a constructive relationship between business, science, and society.
Collapse
Affiliation(s)
- Naomi L. B. Wernick
- Department of Biological Sciences, University of Massachusetts Lowell, Lowell, MA 01854
| | - Fred D. Ledley
- Department of Natural and Applied Sciences, Bentley University, Waltham, MA 02452
| |
Collapse
|
11
|
Abstract
IMPORTANCE Understanding the profitability of pharmaceutical companies is essential to formulating evidence-based policies to reduce drug costs while maintaining the industry's ability to innovate and provide essential medicines. OBJECTIVE To compare the profitability of large pharmaceutical companies with other large companies. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study compared the annual profits of 35 large pharmaceutical companies with 357 companies in the S&P 500 Index from 2000 to 2018 using information from annual financial reports. A statistically significant differential profit margin favoring pharmaceutical companies was evidence of greater profitability. EXPOSURES Large pharmaceutical vs nonpharmaceutical companies. MAIN OUTCOMES AND MEASURES The main outcomes were revenue and 3 measures of annual profit: gross profit (revenue minus the cost of goods sold); earnings before interest, taxes, depreciation, and amortization (EBITDA; pretax profit from core business activities); and net income, also referred to as earnings (difference between all revenues and expenses). Profit measures are described as cumulative for all companies from 2000 to 2018 or annual profit as a fraction of revenue (margin). RESULTS From 2000 to 2018, 35 large pharmaceutical companies reported cumulative revenue of $11.5 trillion, gross profit of $8.6 trillion, EBITDA of $3.7 trillion, and net income of $1.9 trillion, while 357 S&P 500 companies reported cumulative revenue of $130.5 trillion, gross profit of $42.1 trillion, EBITDA of $22.8 trillion, and net income of $9.4 trillion. In bivariable regression models, the median annual profit margins of pharmaceutical companies were significantly greater than those of S&P 500 companies (gross profit margin: 76.5% vs 37.4%; difference, 39.1% [95% CI, 32.5%-45.7%]; P < .001; EBITDA margin: 29.4% vs 19%; difference, 10.4% [95% CI, 7.1%-13.7%]; P < .001; net income margin: 13.8% vs 7.7%; difference, 6.1% [95% CI, 2.5%-9.7%]; P < .001). The differences were smaller in regression models controlling for company size and year and when considering only companies reporting research and development expense (gross profit margin: difference, 30.5% [95% CI, 20.9%-40.1%]; P < .001; EBITDA margin: difference, 9.2% [95% CI, 5.2%-13.2%]; P < .001; net income margin: difference, 3.6% [95% CI, 0.011%-7.2%]; P = .05). CONCLUSIONS AND RELEVANCE From 2000 to 2018, the profitability of large pharmaceutical companies was significantly greater than other large, public companies, but the difference was less pronounced when considering company size, year, or research and development expense. Data on the profitability of large pharmaceutical companies may be relevant to formulating evidence-based policies to make medicines more affordable.
Collapse
Affiliation(s)
- Fred D. Ledley
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts
- Department of Management, Bentley University, Waltham, Massachusetts
| | - Sarah Shonka McCoy
- Department of Accountancy, Bentley University, Waltham, Massachusetts
- Department of Accounting, University of New Mexico, Albuquerque, New Mexico
| | - Gregory Vaughan
- Department of Mathematical Sciences, Bentley University, Waltham, Massachusetts
| | - Ekaterina Galkina Cleary
- Center for Integration of Science and Industry, Department of Mathematical Sciences, Bentley University, Waltham, Massachusetts
| |
Collapse
|
12
|
Simon SM, Meldrum H, Ndung’u E, Ledley FD. Representation of Industry in Introductory Biology Textbooks: A Missed Opportunity to Advance STEM Learning. CBE Life Sci Educ 2018; 17:ar61. [PMID: 30444449 PMCID: PMC6755896 DOI: 10.1187/cbe.17-03-0057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Revised: 09/04/2018] [Accepted: 09/17/2018] [Indexed: 06/09/2023]
Abstract
The majority of students who enroll in undergraduate biology courses will eventually be employed in non-STEM (science, technology, engineering, and mathematics) business occupations. This work explores how representations of industry in undergraduate biology textbooks could impact STEM learning for these students and their ability to apply this learning in their chosen work. We used text analysis to identify passages with references to industry in 29 textbooks. Each passage was categorized for relevance to health or environment, for implied positive or negative connotations, and for descriptions of synergy or conflict between science and industry. We found few passages describing applications of STEM learning in non-STEM business occupations and a paucity of content to support context-based learning for students aiming at business careers. A significant number of passages embodied negative connotations regarding industry. Notable passages highlighted irregular or fraudulent business practices or included simplistic caricatures of business practice. We discuss how the representation of industry in these textbooks may impact student engagement, context-based learning, the ability of students to critically apply STEM learning in industry or business occupations, and heuristics that guide intuitive perceptions about the intersection between science and industry.
Collapse
Affiliation(s)
- Sharotka M. Simon
- Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452
- Department of Natural & Applied Sciences, Bentley University, Waltham, MA 02452
| | - Helen Meldrum
- Department of Natural & Applied Sciences, Bentley University, Waltham, MA 02452
| | - Eric Ndung’u
- Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452
| | - Fred D. Ledley
- Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452
- Department of Natural & Applied Sciences, Bentley University, Waltham, MA 02452
- Department of Management, Bentley University, Waltham, MA 02452
| |
Collapse
|
13
|
Affiliation(s)
- Fred D Ledley
- Center for Integration of Science and Industry and the Department of Natural and Applied Sciences, Bentley University, Waltham, Massachusetts
| |
Collapse
|
14
|
Abstract
This work examines the contribution of NIH funding to published research associated with 210 new molecular entities (NMEs) approved by the Food and Drug Administration from 2010-2016. We identified >2 million publications in PubMed related to the 210 NMEs (n = 131,092) or their 151 known biological targets (n = 1,966,281). Of these, >600,000 (29%) were associated with NIH-funded projects in RePORTER. This funding included >200,000 fiscal years of NIH project support (1985-2016) and project costs >$100 billion (2000-2016), representing ∼20% of the NIH budget over this period. NIH funding contributed to every one of the NMEs approved from 2010-2016 and was focused primarily on the drug targets rather than on the NMEs themselves. There were 84 first-in-class products approved in this interval, associated with >$64 billion of NIH-funded projects. The percentage of fiscal years of project funding identified through target searches, but not drug searches, was greater for NMEs discovered through targeted screening than through phenotypic methods (95% versus 82%). For targeted NMEs, funding related to targets preceded funding related to the NMEs, consistent with the expectation that basic research provides validated targets for targeted screening. This analysis, which captures basic research on biological targets as well as applied research on NMEs, suggests that the NIH contribution to research associated with new drug approvals is greater than previously appreciated and highlights the risk of reducing federal funding for basic biomedical research.
Collapse
Affiliation(s)
| | - Jennifer M Beierlein
- Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452
- Department of Natural and Applied Sciences, Bentley University, Waltham, MA 02452
| | | | - Laura M McNamee
- Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452
- Department of Natural and Applied Sciences, Bentley University, Waltham, MA 02452
| | - Fred D Ledley
- Center for Integration of Science and Industry, Bentley University, Waltham, MA 02452;
- Department of Natural and Applied Sciences, Bentley University, Waltham, MA 02452
- Department of Management, Bentley University, Waltham, MA 02452
| |
Collapse
|
15
|
Beierlein JM, McNamee LM, Ledley FD. As Technologies for Nucleotide Therapeutics Mature, Products Emerge. Mol Ther Nucleic Acids 2017; 9:379-386. [PMID: 29246316 PMCID: PMC5686430 DOI: 10.1016/j.omtn.2017.10.017] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/29/2017] [Revised: 10/24/2017] [Accepted: 10/24/2017] [Indexed: 11/20/2022]
Abstract
The long path from initial research on oligonucleotide therapies to approval of antisense products is not unfamiliar. This lag resembles those encountered with monoclonal antibodies, gene therapies, and many biological targets and is consistent with studies of innovation showing that technology maturation is a critical determinant of product success. We previously described an analytical model for the maturation of biomedical research, demonstrating that the efficiency of targeted and biological development is connected to metrics of technology growth. The present work applies this model to characterize the advance of oligonucleotide therapeutics. We show that recent oligonucleotide product approvals incorporate technologies and targets that are past the established point of technology growth, as do most of the oligonucleotide products currently in phase 3. Less mature oligonucleotide technologies, such as miRNAs and some novel gene targets, have not passed the established point and have not yielded products. This analysis shows that oligonucleotide product development has followed largely predictable patterns of innovation. While technology maturation alone does not ensure success, these data show that many oligonucleotide technologies are sufficiently mature to be considered part of the arsenal for therapeutic development. These results demonstrate the importance of technology assessment in strategic management of biomedical technologies.
Collapse
Affiliation(s)
- Jennifer M Beierlein
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, 175 Forest Street, Waltham, MA 02452, USA
| | - Laura M McNamee
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, 175 Forest Street, Waltham, MA 02452, USA
| | - Fred D Ledley
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, 175 Forest Street, Waltham, MA 02452, USA; Department of Management, Bentley University, 175 Forest Street, Waltham, MA 02452, USA.
| |
Collapse
|
16
|
Beierlein JM, McNamee LM, Walsh MJ, Kaitin KI, DiMasi JA, Ledley FD. Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities. Clin Ther 2017; 39:1409-1425.e20. [PMID: 28652015 DOI: 10.1016/j.clinthera.2017.06.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Revised: 05/23/2017] [Accepted: 06/05/2017] [Indexed: 12/22/2022]
Abstract
PURPOSE This study examines the complete timelines of translational science for new cardiovascular therapeutics from the initiation of basic research leading to identification of new drug targets through clinical development and US Food and Drug Administration (FDA) approval of new molecular entities (NMEs) based on this research. METHODS This work extends previous studies by examining the association between the growth of research on drug targets and approval of NMEs associated with these targets. Drawing on research on innovation in other technology sectors, where technological maturity is an important determinant in the success or failure of new product development, an analytical model was used to characterize the growth of research related to the known targets for all 168 approved cardiovascular therapeutics. FINDINGS Categorizing and mapping the technological maturity of cardiovascular therapeutics reveal that (1) there has been a distinct transition from phenotypic to targeted methods for drug discovery, (2) the durations of clinical and regulatory processes were significantly influenced by changes in FDA practice, and (3) the longest phase of the translational process was the time required for technology to advance from initiation of research to a statistically defined established point of technology maturation (mean, 30.8 years). IMPLICATIONS This work reveals a normative association between metrics of research maturation and approval of new cardiovascular therapeutics and suggests strategies for advancing translational science by accelerating basic and applied research and improving the synchrony between the maturation of this research and drug development initiatives.
Collapse
Affiliation(s)
- Jennifer M Beierlein
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts
| | - Laura M McNamee
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts
| | - Michael J Walsh
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts
| | - Kenneth I Kaitin
- Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts
| | - Joseph A DiMasi
- Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts
| | - Fred D Ledley
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts; Department of Management, Bentley University, Waltham, Massachusetts.
| |
Collapse
|
17
|
Adams RM, Wang M, Crane AM, Brown B, Darlington GJ, Ledley FD. Effective Cryopreservation and Long-Term Storage of Primary Human Hepatocytes with Recovery of Viability, Differentiation, and Replicative Potential. Cell Transplant 2017; 4:579-86. [PMID: 8714779 DOI: 10.1177/096368979500400607] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Despite reports of successful cryopreservation of primary human hepatocytes, existing methods do not produce sufficient recovery of viable cells to meet the needs of basic research or clinical trials of hepatocellular transplantation. We now describe a protocol for efficient cryopreservation of primary human hepatocytes using University of Wisconsin (UW) solution, fetal bovine serum, and dimethyl sulfoxide (DMSO). This method provides >90% viability of differentiated, primary human hepatocytes 8 mo after cryopreservation as measured by trypan blue exclusion, preserves hepatocyte morphology, liver-specific gene expression α1 antitrypsin), and replication. The effectiveness of UW solution as a cryopreservative agent suggests that metabolic as well as ultrastructural factors may be important in the effective cryopreservation of primary human hepatocytes. The present method represents an effective protocol for cryopreserving differentiated primary human hepatocytes for research. This method may allow characterization and banking of human hepatocytes for clinical applications, including hepatocellular transplantation and hepatic assist devices.
Collapse
Affiliation(s)
- R M Adams
- Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | | | |
Collapse
|
18
|
Abstract
While timelines for clinical development have been extensively studied, there is little data on the broader path from initiation of research on novel drug targets, to approval of drugs based on this research. We examined timelines of translational science for 138 drugs and biologicals approved by the FDA from 2010-2014 using an analytical model of technology maturation. Research on targets for 102 products exhibited a characteristic (S-curve) maturation pattern with exponential growth between statistically defined technology initiation and established points. The median initiation was 1974, with a median of 25 years to the established point, 28 years to first clinical trials, and 36 years to FDA approval. No products were approved before the established point, and development timelines were significantly longer when the clinical trials began before this point (11.5 vs 8.5 years, p<0.0005). Technological maturation represents the longest stage of translation, and significantly impacts the efficiency of drug development.
Collapse
Affiliation(s)
- Laura M. McNamee
- Center for Integration of Science and Industry, Department of Natural and Applied Sciences, Bentley University, Waltham, Massachusetts, United States of America
- * E-mail:
| | - Michael Jay Walsh
- Center for Integration of Science and Industry, Department of Natural and Applied Sciences, Bentley University, Waltham, Massachusetts, United States of America
| | - Fred D. Ledley
- Center for Integration of Science and Industry, Department of Natural and Applied Sciences, Bentley University, Waltham, Massachusetts, United States of America
- Department of Management, Bentley University, Waltham, Massachusetts, United States of America
| |
Collapse
|
19
|
Beierlein JM, McNamee LM, Walsh MJ, Ledley FD. Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity. Clin Ther 2015; 37:1643-51.e3. [PMID: 26243074 DOI: 10.1016/j.clinthera.2015.07.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Revised: 07/07/2015] [Accepted: 07/08/2015] [Indexed: 01/04/2023]
Abstract
PURPOSE This article examines the current status of translational science for Alzheimer's disease (AD) drug discovery by using an analytical model of technology maturation. Previous studies using this model have demonstrated that nascent scientific insights and inventions generate few successful leads or new products until achieving a requisite level of maturity. This article assessed whether recent failures and successes in AD research follow patterns of innovation observed in other sectors. METHODS The bibliometric-based Technology Innovation Maturation Evaluation model was used to quantify the characteristic S-curve of growth for AD-related technologies, including acetylcholinesterase, N-methyl-d-aspartate (NMDA) receptors, B-amyloid, amyloid precursor protein, presenilin, amyloid precursor protein secretases, apolipoprotein E4, and transactive response DNA binding protein 43 kDa (TDP-43). This model quantifies the accumulation of knowledge as a metric for technological maturity, and it identifies the point of initiation of an exponential growth stage and the point at which growth slows as the technology is established. FINDINGS In contrast to the long-established acetylcholinesterase and NMDA receptor technologies, we found that amyloid-related technologies reached the established point only after 2000, and that the more recent technologies (eg, TDP-43) have not yet approached this point. The first approvals for new molecular entities targeting acetylcholinesterase and the NMDA receptor occurred an average of 22 years after the respective technologies were established, with only memantine (which was phenotypically discovered) entering clinical trials before this point. In contrast, the 6 lead compounds targeting the formation of amyloid plaques that failed in Phase III trials between 2009 and 2014 all entered clinical trials before the respective target technologies were established. IMPLICATIONS This analysis suggests that AD drug discovery has followed a predictable pattern of innovation in which technological maturity is an important determinant of success in development. Quantitative analysis indicates that the lag in emergence of new products, and the much-heralded clinical failures of recent years, should be viewed in the context of the ongoing maturation of AD-related technologies. Although these technologies were not sufficiently mature to generate successful products a decade ago, they may be now. Analytical models of translational science can inform basic and clinical research results as well as strategic development of new therapeutic products.
Collapse
Affiliation(s)
- Jennifer M Beierlein
- Center for Integration of Science and Industry, Department of Natural and Applied Sciences and Department of Management, Bentley University, Waltham, Massachusetts
| | - Laura M McNamee
- Center for Integration of Science and Industry, Department of Natural and Applied Sciences and Department of Management, Bentley University, Waltham, Massachusetts
| | - Michael J Walsh
- Center for Integration of Science and Industry, Department of Natural and Applied Sciences and Department of Management, Bentley University, Waltham, Massachusetts
| | - Fred D Ledley
- Center for Integration of Science and Industry, Department of Natural and Applied Sciences and Department of Management, Bentley University, Waltham, Massachusetts.
| |
Collapse
|
20
|
Wernick NLB, Ndung’u E, Haughton D, Ledley FD. Positioning genomics in biology education: content mapping of undergraduate biology textbooks. J Microbiol Biol Educ 2014; 15:268-276. [PMID: 25574293 PMCID: PMC4278498 DOI: 10.1128/jmbe.v15i2.724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Biological thought increasingly recognizes the centrality of the genome in constituting and regulating processes ranging from cellular systems to ecology and evolution. In this paper, we ask whether genomics is similarly positioned as a core concept in the instructional sequence for undergraduate biology. Using quantitative methods, we analyzed the order in which core biological concepts were introduced in textbooks for first-year general and human biology. Statistical analysis was performed using self-organizing map algorithms and conventional methods to identify clusters of terms and their relative position in the books. General biology textbooks for both majors and nonmajors introduced genome-related content after text related to cell biology and biological chemistry, but before content describing higher-order biological processes. However, human biology textbooks most often introduced genomic content near the end of the books. These results suggest that genomics is not yet positioned as a core concept in commonly used textbooks for first-year biology and raises questions about whether such textbooks, or courses based on the outline of these textbooks, provide an appropriate foundation for understanding contemporary biological science.
Collapse
Affiliation(s)
- Naomi L. B. Wernick
- Department of Natural and Applied Sciences, Bentley University, Waltham, MA 02452
- Department of Biological Sciences, University of Massachusetts Lowell, MA 01854
| | - Eric Ndung’u
- Department of Mathematical Sciences, Bentley University, Waltham, MA 02452
| | - Dominique Haughton
- Department of Mathematical Sciences, Bentley University, Waltham, MA 02452
| | - Fred D. Ledley
- Department of Natural and Applied Sciences, Bentley University, Waltham, MA 02452
| |
Collapse
|
21
|
Ledley FD, McNamee LM, Uzdil V, Morgan IW. Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies. Gene Ther 2013; 21:188-94. [DOI: 10.1038/gt.2013.72] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Revised: 10/22/2013] [Accepted: 10/24/2013] [Indexed: 01/23/2023]
|
22
|
Abstract
Human Genome Science (HGS) aspired to dominate the emergent field of genomics by discovering expressed gene sequences and developing therapeutic and diagnostic products based on proprietary genes. While HGS’ accomplishments fell short of their own lofty expectations, by the time HGS was acquired by GlaxoSmithKline, the company had extensive intellectual property and had launched a product with >$1 billion market potential. Nevertheless, HGS’ acquisition price was less than the total capital investments in the company. This work examines HGS’ history and accomplishments in the context of the business plan described by the company at their IPO. We focus specifically on the company’s valuation over time, which was highly correlated with general market indices, but negatively correlated with metrics of technical or clinical progress. The history of HGS points to the challenge of accounting for the value created by a science-based business plan. Earnings-based metrics, present value calculations, and “fair value†assessments did not account for HGS’ progress in executing their stated business plan. This work highlights the critical need for accounting practices that credit value to the progress of translational science and enable investors to profit from such investments.
Collapse
|
23
|
|
24
|
Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Brenner M, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, Siegler HF, Barranger JA, Karlsson S, Kohn D, Galpin JE, Raffel C, Hesdorffer C, Ilan J, Cassileth P, O'Shaughnessy J, Kun LE, Das TK, Wong-Staal F, Sobol RE, Haubrich R, Sznol M, Rubin J, Sorcher EJ, Rosenblatt J, Walker R, Brigham K, Vogelzang N, Hersh E, Eck SL. Human gene marker/therapy clinical protocols. Hum Gene Ther 2000; 11:919-79. [PMID: 10779168 DOI: 10.1089/10430340050015536] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
25
|
Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Habib NA. Human gene marker/therapy clinical protocols. Hum Gene Ther 1999; 10:3067-123. [PMID: 10609664 DOI: 10.1089/10430349950016465] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
|
27
|
|
28
|
Affiliation(s)
- D Housman
- Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
| | | |
Collapse
|
29
|
Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC. Human gene marker/therapy clinical protocols. Hum Gene Ther 1997; 8:2301-38. [PMID: 9449381 DOI: 10.1089/hum.1997.8.18-2301] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
|
30
|
Ledley FD, Rosenblatt DS. Mutations in mut methylmalonic acidemia: Clinical and enzymatic correlations. Hum Mutat 1997. [DOI: 10.1002/(sici)1098-1004(1997)9:1<1::aid-humu1>3.3.co;2-g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
31
|
Abstract
Mut methylmalonic acidemia is caused by mutations in the MUT locus encoding the enzyme methylmalonyl CoA mutase. Genotypic and phenotypic variability in this disease has been studied extensively by biochemical and somatic cell genetic techniques, by molecular cloning, and by gene transfer. Mutations have been identified that cause classic mut(o) phenotypes in which there is no detectable enzymatic activity, mut- phenotypes in which there is residual cobalamin-dependent activity, as well as a subset within both mut(o) and mut- phenotypes that exhibit interallelic complementation. These mutations illustrate the position, structure, and function of critical domains within this cobalamin-binding enzyme and provide new insights into the biochemical and clinical consequences of enzyme deficiency.
Collapse
Affiliation(s)
- F D Ledley
- Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, USA
| | | |
Collapse
|
32
|
Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Tiberghien P. Human gene marker/therapy clinical protocols. Hum Gene Ther 1996; 7:2287-313. [PMID: 8953320 DOI: 10.1089/hum.1996.7.18-2287] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
|
33
|
Abstract
The pharmaceutical approach to somatic gene therapy is based on consideration of a gene as a chemical entity with specific physical, chemical and colloidal properties. The genes that are required for gene therapy are large molecules (> 1 x 10(6) Daltons, > 100 nm diameter) with a net negative charge that prevents diffusion through biological barriers such as an intact endothelium, the plasma membrane or the nuclear membrane. New methods for gene therapy are based on increasing knowledge of the pathways by which DNA may be internalized into cells and traffic to the nucleus, pharmaceutical experience with particulate drug delivery systems, and the ability to control gene expression with recombined genetic elements. This article reviews two themes in the development of gene therapies: first, the current approaches involving the administration of cells, viruses and plasmid DNA; second, the emerging pharmaceutical approach to gene therapy based on the pharmaceutical characteristics of DNA itself and methods for advanced drug delivery.
Collapse
Affiliation(s)
- F D Ledley
- GENEMEDICINE, INC., Woodlands, Texas 77381, USA
| |
Collapse
|
34
|
Rosenblatt DS, Ledley FD. [A molecular study of methylmalonic aciduria: structure-function correlations]. Bull Acad Natl Med 1996; 180:1553-63; discussion 1563-4. [PMID: 9102141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Cobalamin (Vitamin B12) non-responsive methylmalonic acidemia is caused by mutations in the MUT locus on chromosome 6p21 encoding the enzyme methylmalonyl CoA mutase (EC 5.4.99.2). This disorder has been extensively studied by biochemical, somatic cell genetic and molecular techniques. Mutations have been identified which cause classic mut(o) phenotypes in which there is no detectable enzymatic activity, as well as mut- phenotypes in which there is residual cobalamin-dependent activity. Mutations which exhibit interallelic complementation have been identified within both of these groups. These mutations illustrate the position, structure, and function of critical domains within this cobalamin binding enzyme and provide new insights into the biochemical and clinical consequences of enzyme deficiency. The homology of the cobalamin binding region has allowed mutations of the mutase to be mapped onto the x-ray structure of methionine synthase (EC 2.1.1.13).
Collapse
Affiliation(s)
- D S Rosenblatt
- Department of Human Genetics, McGill University, Montreal, Quebec
| | | |
Collapse
|
35
|
Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Aebischer P. Human gene marker/therapy clinical protocols. Hum Gene Ther 1996; 7:1621-47. [PMID: 8864763 DOI: 10.1089/hum.1996.7.13-1621] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
|
36
|
|
37
|
Drennan CL, Matthews RG, Rosenblatt DS, Ledley FD, Fenton WA, Ludwig ML. Molecular basis for dysfunction of some mutant forms of methylmalonyl-CoA mutase: deductions from the structure of methionine synthase. Proc Natl Acad Sci U S A 1996; 93:5550-5. [PMID: 8643613 PMCID: PMC39284 DOI: 10.1073/pnas.93.11.5550] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Inherited defects in the gene for methylmalonyl-CoA mutase (EC 5.4.99.2) result in the mut forms of methylmalonic aciduria. mut- mutations lead to the absence of detectable mutase activity and are not corrected by excess cobalamin, whereas mut- mutations exhibit residual activity when exposed to excess cobalamin. Many of the mutations that cause methylmalonic aciduria in humans affect residues in the C-terminal region of the methylmalonyl-CoA mutase. This portion of the methylmalonyl-CoA mutase sequence can be aligned with regions in other B12 (cobalamin)-dependent enzymes, including the C-terminal portion of the cobalamin-binding region of methionine synthase. The alignments allow the mutations of human methylmalonyl-CoA mutase to be mapped onto the structure of the cobalamin-binding fragment of methionine synthase from Escherichia coli (EC 2.1.1.13), which has recently been determined by x-ray crystallography. In this structure, the dimethylbenzimidazole ligand to the cobalt in free cobalamin has been displaced by a histidine ligand, and the dimethylbenzimidazole nucleotide "tail" is thrust into a deep hydrophobic pocket in the protein. Previously identified mut0 and mut- mutations (Gly-623 --> Arg, Gly-626 --> Cys, and Gly-648 --> Asp) of the mutase are predicted to interfere with the structure and/or stability of the loop that carries His-627, the presumed lower axial ligand to the cobalt of adenosylcobalamin. Two mutants that lead to severe impairment (mut0) are Gly-630 --> Glu and Gly-703 --> Arg, which map to the binding site for the dimethylbenzimidazole nucleotide substituent of adenosylcobalamin. The substitution of larger residues for glycine is predicted to block the binding of adenosylcobalamin.
Collapse
Affiliation(s)
- C L Drennan
- Biophysics Research Division and Department of Biological Chemistry, The University of Michigan, Ann Arbor 48109, USA
| | | | | | | | | | | |
Collapse
|
38
|
Ledley FD. Gene therapy in pediatric medicine. Adv Pediatr 1996; 43:1-25. [PMID: 8794173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- F D Ledley
- GeneMedicine, Inc., The Woodlands, Texas, USA
| |
Collapse
|
39
|
Adams RM, Wang M, Crane AM, Brown B, Darlington GJ, Ledley FD. Effective cryopreservation and long-term storage of primary human hepatocytes with recovery of viability, differentiation, and replicative potential. Cell Transplant 1995. [PMID: 8714779 DOI: 10.1016/0963-6897(95)02001-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Despite reports of successful cryopreservation of primary human hepatocytes, existing methods do not produce sufficient recovery of viable cells to meet the needs of basic research or clinical trials of hepatocellular transplantation. We now describe a protocol for efficient cryopreservation of primary human hepatocytes using University of Wisconsin (UW) solution, fetal bovine serum, and dimethyl sulfoxide (DMSO). This method provides > 90% viability of differentiated, primary human hepatocytes 8 mo after cryopreservation as measured by trypan blue exclusion, preserves hepatocyte morphology, liver-specific gene expression (alpha 1 antitrypsin), and replication. The effectiveness of UW solution as a cryopreservative agent suggests that metabolic as well as ultrastructural factors may be important in the effective cryopreservation of primary human hepatocytes. The present method represents an effective protocol for cryopreserving differentiated primary human hepatocytes for research. This method may allow characterization and banking of human hepatocytes for clinical applications, including hepatocellular transplantation and hepatic assist devices.
Collapse
Affiliation(s)
- R M Adams
- Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | | | |
Collapse
|
40
|
Abstract
The epithelial cells of the gastrointestinal tract may be attractive targets for somatic gene therapy. In these studies, we have used rats and mice to explore the feasibility of gene transfer into the small intestinal epithelium using retroviral vectors. The first series of experiments was conducted in mature Sprague-Dawley rats using an ecotropic retroviral vector that has bacterial beta-galactosidase (beta-Gal) as the reporter gene. The vector was introduced into the lumen of ligated segments of terminal ileum. After a 4-hr exposure period, the ligatures were removed. Sham-operated animals were subjected to the same ligation procedure but received only tissue culture medium in the ligated segment. All animals were sacrificed 6 days later, and tissue from both the experimental segment and an upstream control segment was assessed for cytoplasmic beta-Gal activity using X-Gal histochemistry. Expression of the reporter gene was observed in the crypt epithelium of tissue exposed to the vector. In the villus epithelium, high background staining precluded accurate assessment of reporter gene expression. To obviate the latter problem, we sought an alternative reporter gene for which there would be no background staining in control animals. We repeated the experiments with beta-glucuronidase as the reporter gene in MPS VII mutant mice, which are devoid of this enzyme. In these studies, ileal segments exposed to the vector demonstrated expression of the reporter gene in both the crypt and villus epithelium 4 days after exposure. These results indicate that genes can be transferred into the intestinal epithelium using retroviral vectors introduced luminally.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- C Lau
- Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030-3498, USA
| | | | | | | | | | | | | |
Collapse
|
41
|
Ledley FD. Editorial: When is a gene an investigational drug? Expert Opin Investig Drugs 1995. [DOI: 10.1517/13543784.4.9.781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
42
|
Abstract
Although most research on gene therapy has focused on the use of recombinant viruses to deliver genes to cells in vivo, progress also has been made toward developing nonviral, pharmaceutical formulations of genes for in vivo human therapy. Various methods for nonviral gene therapy have been proposed. Some approaches are aimed at developing "artificial viruses" that attempt to mimic the process of viral infection using synthetic materials. Others apply the theory and methods of advanced, particulate drug delivery to deliver DNA to select somatic targets. These approaches employ DNA complexes containing lipid, protein, peptide, or polymeric carriers as well as ligands capable of targeting the DNA complex to cell-surface receptors on the target cell and ligands for directing the intracellular trafficking of DNA to the nucleus. Nonviral systems have been used to deliver genes to the lung, liver, endothelium, epithelium, and tumor cells and have been shown to be generally safe. More than a dozen clinical trials are currently underway using nonviral systems for disease indications including cystic fibrosis and cancer. Future advances in nonviral systems will be based on an emerging appreciation of the biological constraints on the fate and function of DNA within the body and within the cell.
Collapse
Affiliation(s)
- F D Ledley
- GeneMedicine, Inc., The Woodlands, TX 77381-4248, USA
| |
Collapse
|
43
|
|
44
|
Abstract
We studied reporter gene expression in synovial tissue after intra-articular administration of an expression plasmid into the knees of rabbits and rats. In both species, administration of a plasmid encoding beta-galactosidase led to gene expression in the synovial cells lining the joint. Expression correlated with the presence of plasmid DNA in synovial tissue extracts. Studies with a plasmid encoding chloramphenicol acetyltransferase demonstrated that gene expression persists for 2-5 days after administration. Southern blotting demonstrated that the administered plasmid was taken up rapidly by synovial tissue and degraded. By 24 hr after administration, no intact plasmid could be detected by Southern blotting, although small amounts of plasmid could be amplified by PCR up to 7 days. Administration of a plasmid encoding human growth hormone demonstrated that this product could be expressed from synovial cells and secreted into the synovial fluid. The histological distribution of gene expression in synovium resembles the known distribution of particulate materials injected into the joint and suggests that plasmid DNA is taken up by nonspecific endocytosis like other particulate materials during the remodeling of synovial fluid.
Collapse
Affiliation(s)
- J Yovandich
- Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | |
Collapse
|
45
|
Abstract
Retrovirus infection is normally limited to cells within a specific host range which express a cognate receptor that is recognized by the product of the env gene. We describe retrovirus infection of cells outside of their normal host range when the infection is performed in the presence of a replication-defective adenovirus (dl312). In the presence of adenovirus, several different ecotropic vectors are shown to infect human cell lines (HeLa and PLC/PRF), and a xenotropic vector is shown to infect murine cells (NIH 3T3). Infectivity is demonstrated by 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) staining, selection with G418 for neomycin resistance, and PCR identification of the provirus in infected cells. Infectivity is quantitatively dependent upon both the concentration of adenovirus (10(6) to 10(8) PFU/ml) and the concentration of retrovirus. Infection requires the simultaneous presence of adenovirus in the retrovirus infection medium and is not stimulated by preincubation and removal of adenovirus from the cells before retrovirus infection. The presence of adenovirus is shown to enhance the uptake of fluorescently labeled retrovirus particles into cells outside of their normal host range, demonstrating that the adenovirus enhances viral entry into cells in the absence of the recognized cognate receptor. This observation suggests new opportunities for developing safe retroviral vectors for gene therapy and new mechanisms for the pathogenesis of retroviral disease.
Collapse
Affiliation(s)
- R M Adams
- Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030
| | | | | | | |
Collapse
|
46
|
Affiliation(s)
- F D Ledley
- GeneMedicine, Inc., Woodlands, Texas 77054, USA
| |
Collapse
|
47
|
Abstract
Non-viral gene therapies are currently under development that employ drug-delivery methods for targeting genes to selected cells in the body, where they express therapeutic gene products. Various methods have been described for non-viral gene therapy, ranging from the direct intramuscular injection of purified DNA to the systemic administration of formulations comprising DNA and lipids, proteins, peptides, or polymers. Products for non-viral gene therapies are designed both for direct administration to patients by conventional routes and for expression of a therapeutic product over a finite period of time in a manner similar to conventional medicines. Initial preclinical and clinical studies indicate that non-viral gene delivery methods exhibit safety profiles similar to conventional pharmaceutical or biological products. Clinical trials have been proposed, or are currently under way, to assess the applicability of non-viral gene therapy for a variety of disorders, including cystic fibrosis, cancer, and peripheral vascular disease. Non-viral techniques may soon allow gene therapy to be applied in clinical practice alongside conventional medicines for the treatment of common diseases.
Collapse
|
48
|
Ledley FD. Therapeutic Promise of Molecular Genetics. J Invest Dermatol 1994. [DOI: 10.1038/jid.1994.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
49
|
Abstract
The application of molecular genetics to medicine is based on the observation that even common diseases have both genetic and environmental components. Conventional medicines are often effective in managing environmental components of disease but are generally ineffective in managing genetic diseases or manipulating the genetic component of multifactorial diseases. The development of therapies aimed at the genetic component of disease will require non-conventional medicinal applications of molecular genetics. Various approaches have been proposed such as diagnosing the propensity for disease to facilitate early intervention with conventional therapies, selectively eliminating mutant genes from human populations, correcting mutations in human chromosomes, and using genes as medicines to modify the genetic components of disease. Of these, it is the development of gene medicines that has the greatest practical potential. The combination of conventional medicines, focused on the environmental components of disease, and gene medicines, focused on the genetic components, will provide the clinician with broad options for managing health and disease. The challenge to molecular biology is to develop gene medicines that are effective, safe, and socially acceptable, and therapies that map well to established clinical practice and may be employed efficaciously alongside conventional medicines.
Collapse
Affiliation(s)
- F D Ledley
- Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030
| |
Collapse
|
50
|
Abstract
The authors established a means of effective gene transfer into human thyroid follicular cells via retroviral-mediated mechanisms. Using specific harvest and culture techniques, we investigated the selection of human thyroid cells in serum-free media. Normal adult human thyroid tissue was obtained after thyroidectomy from fresh specimens sent for frozen-section analysis. Follicular cells were harvested and grown in hormonally defined, serum-free media to prevent fibroblast growth with selection for differentiated function assessed by immunohistochemical staining for thyroglobulin. The efficiency of gene transfer into human thyroid cells was compared between the zen-beta-gal and LNL6 retroviral vectors. The zen-beta-gal retrovirus encodes the product beta-galactosidase, and gene expression was demonstrated by histochemical staining in 0.1% to 1% of the cells. An improved efficiency of 2% to 3% transduction was demonstrated using the LNL6 vector which carries the gene for neomycin resistance (NEO-R). Polymerase chain reaction (PCR) identification of the integrated proviral sequence (NEO-R gene) with Southern blot confirmation was used to quantitate LNL6 transductions and compare confluent versus actively dividing cell cultures. Follicular cell gene therapy has significant potential for treating congenital or acquired diseases of the thyroid as well as disorders of circulating proteins such as diabetes, hypopituitarism, and hemophilia. The ability to culture human follicular cells and perform effective gene transfer is paramount in the eventual realization of thyroid gene therapy.
Collapse
Affiliation(s)
- B W O'Malley
- Department of Cell Biology, Baylor College of Medicine, Houston, Tex
| | | | | | | |
Collapse
|